Unknown

Dataset Information

0

Identification of a flavonoid isolated from plum (Prunus domestica) as a potent inhibitor of Hepatitis C virus entry.


ABSTRACT: Hepatitis C virus (HCV) infection is a major cause of chronic liver diseases that often requires liver transplantation. The standard therapies are limited by severe side effects, resistance development, high expense and in a substantial proportion of cases, fail to clear the infection which bespeak the need for development of well-tolerated antivirals. Since most of the drug development strategies target the replication stage of viral lifecycle, the identification of entry inhibitors might be crucial especially in case of liver-transplant recipients. In the present study we have evaluated fruits which are known for their hepatoprotective effects in order to screen for entry inhibitors. We report the identification of a flavonoid, rutin, isolated from Prunus domestica as a new HCV entry inhibitor. Characterization and confirmation of the chemical structure was done by LC-ESI-MS, NMR and IR spectral analyses. Rutin significantly inhibited HCV-LP binding to hepatoma cells and inhibited cell-culture derived HCV (HCVcc) entry into hepatoma cells. Importantly, rutin was found to be non-toxic to hepatoma cells. Furthermore, rutin inhibits the early entry stage of HCV lifecycle possibly by directly acting on the viral particle. In conclusion, rutin is a promising candidate for development of anti-HCV therapeutics in the management of HCV infection.

SUBMITTER: Bose M 

PROVIDER: S-EPMC5479801 | biostudies-other | 2017 Jun

REPOSITORIES: biostudies-other

altmetric image

Publications

Identification of a flavonoid isolated from plum (Prunus domestica) as a potent inhibitor of Hepatitis C virus entry.

Bose Mihika M   Kamra Mohini M   Mullick Ranajoy R   Bhattacharya Santanu S   Das Saumitra S   Karande Anjali A AA  

Scientific reports 20170621 1


Hepatitis C virus (HCV) infection is a major cause of chronic liver diseases that often requires liver transplantation. The standard therapies are limited by severe side effects, resistance development, high expense and in a substantial proportion of cases, fail to clear the infection which bespeak the need for development of well-tolerated antivirals. Since most of the drug development strategies target the replication stage of viral lifecycle, the identification of entry inhibitors might be cr  ...[more]

Similar Datasets

| S-EPMC6963518 | biostudies-literature
| S-EPMC4069073 | biostudies-literature
2019-07-30 | GSE131832 | GEO
2020-05-15 | GSE150606 | GEO
| S-EPMC6312543 | biostudies-literature
| S-EPMC4090149 | biostudies-literature
| S-EPMC7775438 | biostudies-literature
| S-EPMC7679426 | biostudies-literature
| S-EPMC2936744 | biostudies-literature
| S-EPMC6832200 | biostudies-literature